Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958031 · ClinicalTrials.gov registry record · Phase 2
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04958031 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 41 participants.
The verdict
NCT04958031, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Interventions
- DRUG Placebo
- DRUG CVL-871 1.0 mg
- DRUG CVL-871 3.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958031
The ClinicalTrials.gov registry entry for NCT04958031 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04958031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04958031 about?
NCT04958031 is a clinical study titled "A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy". The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
What is the current status of trial NCT04958031?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-06-22. Estimated completion is 2025-02-12.
What interventions are being tested in trial NCT04958031?
The interventions under investigation include: Placebo (DRUG), CVL-871 1.0 mg (DRUG), CVL-871 3.0 mg (DRUG).
Who is sponsoring clinical trial NCT04958031?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.